The difference between information and
expert, data-driven actionable intelligence

February 2015

Welcome to the February 2015 issue of CMC Market Outlook

This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.

Enjoy the February issue!

The PharmSource Team

 

Clinical-Scale Injectables Manufacturing and Packaging

In the world of CMC development services, there recently have been some notable acquisitions of companies with clinical scale injectables operations. AMRI acquired Oso Biopharmaceuticals in late 2014, and Piramal acquired Coldstream in January 2015. These acquisitions bring strategic synergies that poise both AMRI and Piramal well in a market with significant anticipated growth, which is fueled by ample financial investments received by early stage bio/pharmaceutical companies since 2013.

To learn more about companies that offer clinical dose manufacturing and packaging services, a look into the PharmSource STRATEGIC ADVANTAGE database reveals 205 companies located in 29 countries around the world, with capabilities including… read on
 

Implications of Pfizer Acquisition of Hospira for the CMO Industry

Pfizer’s announcement that it will acquire Hospira sent a ripple through the pharmaceutical industry, but a wave through the CMO industry. At a time when the injectables pipeline is expanding thanks to biologics and oncology candidates, a significant change in One2One’s involvement in the injectables CMO market could cause a substantial shortfall in the CMO industry’s ability to meet expected demand.

While it is too soon to gauge the ultimate impact of the acquisition on the injectable CMO market situation, we can make some initial assessment of what the acquisition might mean… read on
 

CMOs Out in Force at JP Morgan

The New Year brings the year’s biggest health care industry showcase, the JP Morgan Healthcare Conference, held January 12-16. Contract services providers were well-represented, with the usual CRO presenters (Quintiles, Icon, Parexel and Charles River Laboratories) joined by a growing number of CMOs: Catalent, Parexel, Lonza, Albany Molecular Research (AMRI), Wuxi Pharmatech, Westpharma, and Samsung Biologics all gave well-attended presentations. The CEOs of Hospira and Baxter also presented, though their presentations focused on non-CMO businesses.

M&A involving CMOs and CDMOs was a big topic of discussion. Many of the presenting CMOs claimed… read on
 

Catching a Wave: How Much Will CMOs Benefit From Biosimilars?

The second wave of biosimilars is starting to hit the US and European markets. Biopharma companies are already starting to develop the third wave.

  • Only 10% of the first wave of biosimilars was outsourced. How much will CMOs benefit from the coming generations?
  • Can start-up biosimilar companies compete with Big Pharma and Big Generics?
    • What can CMOs do to get a bigger piece of the future opportunity?

       

      Coming soon!

      CMO Market Penetration as Evidenced by
      Outsourced NDA Approvals, 2015 edition

      This new data-rich Trend Report coming soon from PharmSource addresses these questions and more:

      • What share of new FDA and EMA approvals are dose CMOs getting?
      • Which types of pharma companies are most likely to outsource dose manufacture?
      • Are big pharma companies favoring certain CMOs?

      This report will help you benchmark your performance against your peers and formulate and/or refine your CMO business strategy.

      Click here for more information and to be notified when this Trend Report becomes available.
       

      #FindPharmSource

      PharmSource is sponsoring DCAT’s 2015 PharmaChem Outlook: The Market Opportunities and Challenges (with Networking Reception) on Monday, March 16 from 1:15 pm to 4:30 pm in the Empire Room. A networking reception will follow from 4:30 pm to 6:00 pm in the Vanderbilt Room.

       

      PharmSource STRATEGIC ADVANTAGE

      Let PharmSource be your market intelligence guide.

      PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.

      See for yourself how this resource gives you vital tools for understanding the industry.

      To request a test-drive today, contact Nathaniel Celentano at nathaniel@pharmsouce.com / 1-703-383-4903, ext. 112 (ET USA).